Oxford Asset Management LLP Invests $517,000 in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Oxford Asset Management LLP purchased a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 4,894 shares of the medical equipment provider’s stock, valued at approximately $517,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Roman Butler Fullerton & Co. acquired a new stake in Zimmer Biomet in the fourth quarter valued at approximately $473,000. KLCM Advisors Inc. acquired a new stake in shares of Zimmer Biomet during the 4th quarter valued at $7,825,000. Peddock Capital Advisors LLC bought a new stake in Zimmer Biomet during the 4th quarter worth $654,000. Van ECK Associates Corp increased its holdings in Zimmer Biomet by 5.9% in the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider’s stock worth $417,814,000 after purchasing an additional 218,688 shares in the last quarter. Finally, Reinhart Partners LLC. raised its position in Zimmer Biomet by 34.4% in the fourth quarter. Reinhart Partners LLC. now owns 86,755 shares of the medical equipment provider’s stock valued at $9,164,000 after purchasing an additional 22,220 shares during the last quarter. 88.89% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now directly owns 8,768 shares of the company’s stock, valued at $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ZBH shares. Royal Bank of Canada reduced their price target on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a report on Friday, February 7th. Raymond James dropped their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. JMP Securities reissued a “market outperform” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, Barclays decreased their price objective on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a report on Monday, February 10th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $101.46 on Friday. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The firm’s 50-day moving average price is $105.81 and its 200-day moving average price is $106.59. The firm has a market capitalization of $20.07 billion, a P/E ratio of 22.80, a P/E/G ratio of 1.95 and a beta of 0.84. Zimmer Biomet Holdings, Inc. has a 1-year low of $93.10 and a 1-year high of $123.96.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period last year, the company earned $2.20 EPS. Equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.95%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.